Athira Pharma, Inc.

NASDAQ (USD): Athira Pharma, Inc. (ATHA)

Last Price

0.597

Today's Change

+0.169 (39.48%)

Day's Change

0.548 - 0.676

Trading Volume

166,658,328

Overview

Market Cap

23 Million

Shares Outstanding

38 Million

Avg Volume

948,673

Avg Price (50 Days)

0.90

Avg Price (200 Days)

2.35

PE Ratio

-0.21

EPS

-2.97

Earnings Announcement

07-Nov-2024

Previous Close

0.43

Open

0.59

Day's Range

0.5479 - 0.6761

Year Range

0.412 - 4.298

Trading Volume

167,004,585

Price Change Highlight

1 Day Change

44.80%

5 Day Change

34.76%

1 Month Change

37.79%

3 Month Change

-80.93%

6 Month Change

-69.61%

Ytd Change

-78.55%

1 Year Change

-64.58%

3 Year Change

-95.72%

5 Year Change

-96.38%

10 Year Change

-96.38%

Max Change

-96.38%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment